Mood Disorders Biomarker Services
Major Depressive Disorder (MDD)
Service OfferingActive
Key Facts
About The Siesta Group
The Siesta Group is a Vienna-based, neuroscience-focused service provider that empowers CNS drug development through advanced analysis of EEG, sleep, and activity data. Leveraging over 20 years of experience, proprietary AI-powered analysis tools, and a strong scientific network, the company helps sponsors identify biomarkers and endpoints for conditions ranging from sleep disorders to neurodegenerative diseases. It operates as a trusted partner to over 30 leading sponsors and CROs, offering a full suite of clinical trial services from feasibility to data visualization, all while maintaining rigorous compliance standards.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |